MAPT and Alzheimer disease: At last, to further confirm that the therapeutic effect of Chk1 inhibitor GDC-0575 in the AD mice is through targeting the Chk1-CIP2A-PP2A-tau/APP signaling axis, we detected the changes of these key proteins in the mouse models.